Table 7.
TKI and chemotherapy or other agents in blastic phase of chronic myeloid leukemia.
| Study |
Patients n° |
Regimen | Hematologic response | Cytogenetic response | Median survival |
|---|---|---|---|---|---|
| COMBINATION WITH CHEMOTHERAPY | |||||
| Rea et al. (100) | 13 (ly-BP) |
Imatinib plus VCR/DEX | CHR 85% | MCyR 46% CCyR 31% |
n.r. |
| Fruehauf et al. (101) | 16 (my-BP) |
Imatinib plus MTZ/VP-16 | HR 81% CHR n.r. |
n.r. | 6.4 months |
| Quintas-Cardama et al. (102) | 19 (my-BP) |
Imatinib plus IDA/ldARA-C | HR 74% CHR 47% |
CCyR 16% | 5 months |
| Deau et al. (103) | 36 (my-BP) |
Imatinib plus 7/3 ARA-C/DNM | HR 78% CHR 56% |
MCyR 41% CCyR 30% |
16 months |
| Milojkovic et al. (104) | 4 (ly-BP / my-BP) |
Dasatinib plus FLAG/IDA | CHR 100% | MCyR 100% CCyR 75% MMR 75% |
n.r. |
| Strati et al. (105) | 42 (ly-BP) | Imatinib or dasatinib plus HyperCVAD | CHR 90% | CCyR 58% MMR 50% CMR 25% |
17 months |
| Jain et al. (106) | 195 (ly-BP/my-BP) |
Different TKI and chemo regimens | HR 64% | CCyR 29% MMR 16% |
12 months |
| COMBINATION WITH OTHER AGENTS | |||||
| Oki et al. (107) | 10 (my-BP) |
Imatinib plus decitabine | HR 30% CHR 20% |
MCyR 20% | 3.5 months |
| Fang et al. (108) | 12 (my-BP) |
Imatinib plus omacetaxine | HR 91% CHR 58% |
MCyR 91% CCyR 25% |
75%@1-yr |
| Ghez et al. (109) | 5 (my-PB) |
Dasatinib or nilotinib plus azacytidine | CHR 100% | MCyR 80% CCyR 40% MMR 40% |
24 months |
| Ruggiu et al. (110) | 11 (my-BP) |
Dasatinib or nilotinib or ponatinib plus azacytidine | CHR 71% | CCyR 43% MMR 15% |
28.1 months |
Ly-BP, lymphoid blastic phase (in some trials also de-novo Philadelphia-chromosome positive acute lymphoblastic leukemia are included); My-BP, myeloid blastic phase; VCR/DEX, vincristine/dexamethasone; MTZ/VP-16, mitoxantrone/etoposide; IDA/ldARA-C, idarubicin/low-dose cytrarabine; ARA-C/DNM, cytarabine/daunorubicin; FLAG/IDA, fludarabine/cytarabine/G-CSF/idarubicin; HR, hematologic response; CHR, complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; CMR, complete molecular response.